Trial Profile
Clinical manifestation of gastrointestinal bleeding in patients taking Dabigatran,rivaroxaban, Apixaban (Nonvitamin K oral anticoagulants) for non-valvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2018 New trial record